October 2, 2026

Rapport Therapeutics (RAPP) Stock Analysis: Exploring a Promising 91% Upside in the Biotech Sector

Rapport Therapeutics, Inc. (NASDAQ: RAPP), a rising player in the biotechnology industry, is gaining traction with investors due to its ambitious focus on developing transformative treatments..

AtaiBeckley Inc. (ATAI): Investor Outlook on a Biotech Innovator with a Promising 10% Upside

AtaiBeckley Inc. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company with a focus on mental health treatments, is capturing attention in the healthcare sector. Based in New York,..

Autolus Therapeutics plc (AUTL) Stock Analysis: A Biotech Gem with 371.62% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a pioneering player in the biotechnology sector, is capturing investor attention with a staggering potential upside of 371.62%, according to the..

Oruka Therapeutics, Inc. (ORKA): Investor Outlook with 85.81% Potential Upside and Exclusive Buy Ratings

Oruka Therapeutics, Inc. (NASDAQ: ORKA) is catching the eye of investors with its impressive potential upside of 85.81%, according to analyst ratings. This clinical-stage biopharmaceutical company,..

Celcuity Inc. (CELC) Stock Analysis: A Biotech Powerhouse with 112% Upside Potential

Celcuity Inc. (NASDAQ: CELC), a clinical-stage biotechnology company headquartered in Minneapolis, Minnesota, has captured the attention of investors with its promising pipeline of targeted therapies for..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Unlocking a 36% Upside Potential in the Healthcare Sector

In the dynamic landscape of the healthcare sector, Eton Pharmaceuticals, Inc. (NASDAQ: ETON) is capturing investor attention with its promising portfolio targeting rare diseases. With a..

Standard BioTools Inc. (LAB) Stock Analysis: Exploring an 85% Upside Potential

Standard BioTools Inc. (NASDAQ: LAB) is attracting investor attention with a compelling 85.36% potential upside, according to analyst target price projections. Operating within the healthcare sector,..

KalVista Pharmaceuticals (KALV): An Insight into Its Future Post-Privatization

KalVista Pharmaceuticals, Inc. (KALV), a notable player in the biotechnology industry with a market capitalization of $1.44 billion, has recently undergone a significant transition. As of..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a Challenging Landscape with a 44% Potential Downside

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) stands at the forefront of biotechnology innovation, yet faces significant challenges that investors must carefully navigate. With a market capitalization..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Potential 125% Upside in the Biotech Arena

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology firm, is making waves in the healthcare sector with its innovative approach to developing precision medicines targeting fibroblast..

RxSight, Inc. (RXST) Stock Analysis: Evaluating the 59% Upside Potential Amidst Volatile Performance

RxSight, Inc. (NASDAQ: RXST), a commercial-stage leader in the healthcare sector focused on medical devices, has garnered investor interest due to its unique product offering. Specializing..

Abivax SA (ABVX) Stock Analysis: A Biotech with a 72% Upside Potential

Abivax SA (ABVX), a Paris-based biotechnology firm, is capturing the attention of investors with its promising pipeline and significant upside potential. Operating within the healthcare sector,..

Prothena Corporation plc (PRTA): Investor Outlook on a Biotech Stock with 150% Potential Upside

Prothena Corporation plc (NASDAQ: PRTA), a biopharmaceutical company based in Dublin, Ireland, is making waves in the healthcare sector with its focus on novel therapies for..

CeriBell, Inc. (CBLL) Stock Analysis: Exploring a Promising 18.59% Potential Upside in the Healthcare Sector

CeriBell, Inc. (NASDAQ: CBLL), a cutting-edge player in the medical devices industry, is capturing the attention of investors with its promising potential upside of 18.59%. Specializing..

Stoke Therapeutics, Inc. (STOK) Stock Analysis: Unveiling a Promising 78.63% Potential Upside in Biotechnology

Stoke Therapeutics, Inc. (NASDAQ: STOK) has rapidly emerged as a formidable player in the biotechnology sector, attracting substantial investor interest due to its innovative approach to..

Kamada Ltd. (KMDA) Stock Analysis: Unlocking a 64.63% Potential Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), an Israeli-based player in the healthcare sector, stands out as an attractive proposition for investors eyeing the drug manufacturing industry, particularly in..

Verastem, Inc. (VSTM) Stock Analysis: Unveiling an 85% Potential Upside Amidst Robust Revenue Growth

Verastem, Inc. (NASDAQ: VSTM), a promising player in the biotechnology sector, has captured investor attention due to its impressive revenue growth and a substantial potential upside..

MeiraGTx Holdings plc (MGTX) Stock Analysis: Exploring a 160% Upside Potential in Biotech Innovations

MeiraGTx Holdings plc (NASDAQ: MGTX), a prominent player in the biotechnology sector, is attracting noteworthy attention from investors with its robust pipeline of genetic medicine developments..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Insights into a Challenging Market Landscape and Growth Potential

Fulgent Genetics, Inc. (NASDAQ: FLGT) stands at a pivotal intersection in the diagnostics and research industry, particularly as the healthcare sector continues to evolve post-pandemic. With..

Humacyte, Inc. (HUMA) Stock Analysis: Unlocking a 267% Potential Upside in the Biotech Sector

Investors with an eye on Humacyte, Inc. (NASDAQ: HUMA) may find themselves at the intersection of innovation and opportunity in the burgeoning biotechnology sector. With a..

Search

Funds

October 2, 2026

Search

Funds

October 2, 2026

FTSE 100

Funds